
Virion Therapeutics: A global biotech firm innovating vaccines for cancers and chronic viral infections.
Founded as a clinical-stage biopharmaceutical company, Virion Therapeutics focuses on developing innovative T cell-based immunotherapies to treat cancer and chronic infectious diseases. The company's core mission is to enhance and broaden CD8+ T cell responses using genetically encoded checkpoint modifiers (CPMs), aiming to provide more effective treatments for patients globally. Virion Therapeutics leverages cutting-edge biotechnology to create vaccines that address significant unmet medical needs in oncology and infectious disease markets.
Notable figures affiliated with Virion Therapeutics include leading scientists and industry experts in immunotherapy and vaccine development. The company has attracted investment from prominent venture capital firms specializing in biotech innovations. Key achievements include successful preclinical trials demonstrating the efficacy of their CPMs in enhancing immune responses. Virion Therapeutics' impact lies in its potential to revolutionize treatment paradigms for cancer and chronic infections, offering hope for improved patient outcomes worldwide.

Vir Biotechnology
vir.bio

Viriom
viriom.com

IconOVir Bio
iconovir.com

Therabiol
Virsti Therapeutics

Precision Virologics

Viracta Therapeutics
viracta.com

A2 Biotherapeutics
a2bio.com

Via Nova Therapeutics
vianovatx.com

Vita Therapeutics

ViTToria Biotherapeutics
vittoriabio.com

Triumvira Immunologics
triumvira.com

LTZ Therapeutics

Vyriad
vyriad.com

VintaBio
vintabio.com
Companies similar to Virion Therapeutics include Vir Biotechnology, Viriom, IconOVir Bio and Therabiol.
Virion Therapeutics was founded in 2018.
Virion Therapeutics' headquarters is located in Newark, DE, US.
As of Jan 1, 2021, Virion Therapeutics has raised a total of $14.1M (USD).
Virion Therapeutics has 8 employees as of Feb 5, 2024.